|Day Low/High||169.76 / 172.99|
|52 Wk Low/High||130.09 / 176.64|
11 Abstracts to be Presented at ESC Congress 2016
A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.
RBC Capital analysts say this would free 'trapped value' on drug treatments.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.
Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.
Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.
Stocks secure robust gains after the latest labor market snapshot breezes past expectations.
The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.
The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.
The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.
The sector seems to be rebounding after tumbling by more than 40%.
The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.
Collaboration Will Advance Highly Targeted, Patient-Specific Treatment Approach
The bifurcation can be seen just by looking at Apple's recent results.
That may be the best way to get through the notorious month of August.
A healthy pullback in Amgen would create a low-risk buying opportunity.
Amgen (AMGN) stock is up on Thursday afternoon following the company’s solid earnings and revenue results for the 2016 second quarter, and upbeat guidance.
Facebook (FB) smashed earnings expectations--again. Shares are hitting record highs in the pre-market.
Stocks remain very unconcerned about rates, despite the odds of a fall increase slightly rising.
Amgen (AMGN) reported 2016 second quarter earnings after the closing bell today that beat analysts' expectations.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Amgen investors have had a rough ride. The stock is down about 3% year to date, but the second half of the year could get interesting.
Cramer is no fan of Chesapeake Energy and thinks Gartner has great growth.
Buying Yahoo!'s core assets is the start of something very big, Cramer says.